Ganoderma lucidum Protein May Help Breast Cancer Prognosis
Author Information
Author(s): Zuo Zanwen, Wen Ruihua, Jing Shuang, Chen Xianghui, Liu Ruisang, Xue Jianping, Zhang Lei, Li Qizhang
Primary Institution: Huaibei Normal University, China
Hypothesis
Can the immunomodulatory protein FIP-glu from Ganoderma lucidum improve the prognosis of breast cancer by regulating key genes?
Conclusion
The study identified six risk genes for breast cancer prognosis and suggested that FIP-glu could be a promising treatment to improve outcomes for patients with LumA breast cancer.
Supporting Evidence
- Six risk genes were identified that correlate with breast cancer prognosis.
- FIP-glu was shown to significantly regulate the expression of these risk genes.
- The study constructed a prognostic model that predicts patient outcomes based on gene expression.
- Patients with high-risk scores had lower survival rates compared to those with low-risk scores.
- FIP-glu attenuated the tumor-promoting effects of TMEM63C in breast cancer cells.
Takeaway
This study found that a special protein from a mushroom might help people with a type of breast cancer feel better and live longer by changing how certain genes work.
Methodology
The study used bioinformatics to analyze gene expression data from breast cancer patients and validated findings through laboratory assays.
Participant Demographics
413 LumA breast cancer samples and 113 normal samples were analyzed.
Statistical Information
P-Value
4.22 × 10−6
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website